Polyxeni Karakosta

Dr. Polyxeni Karakosta

Clinical Microbiology Laboratory, Medical School, Attikon University General Hospital, National and Kapodistrian University of Athens, Athens, Greece.
orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 July 2013 in Paediatric and Perinatal Epidemiology
Verified
Journal Article
Closed access
PDF file
PKPolyxeni Karakosta
Polyxeni Karakosta
VGVaggelis Georgiou
Vaggelis Georgiou
EFEleni Fthenou
Eleni Fthenou
EPEleni Papadopoulou
Eleni Papadopoulou
TRTheano Roumeliotaki
Theano Roumeliotaki
LCLeda Chatzi
Leda Chatzi

1 June 2016 in Metabolism
Verified
Journal Article
Closed access
PKPolyxeni Karakosta
Polyxeni Karakosta
TRTheano Roumeliotaki
Theano Roumeliotaki
GCGeorgia Chalkiadaki
Georgia Chalkiadaki
KSKaterina Sarri
Katerina Sarri
MVMaria Vassilaki
Maria Vassilaki
LCLeda Chatzi
Leda Chatzi

1 January 2011 in Journal of Thyroid Research
Verified
Journal Article
Open access
PDF file
PKPolyxeni Karakosta
Polyxeni Karakosta
LCLeda Chatzi
Leda Chatzi
EBEmmanouil Bagkeris
Emmanouil Bagkeris
VDVasiliki Daraki
Vasiliki Daraki
DADimitris Alegakis
Dimitris Alegakis
MKMarilena Kampa
Marilena Kampa
Estimation and interpretation of thyroid function tests in pregnant women is of utmost importance for maternal, fetal and neonatal health. Our objective was to calculate laboratory- and geography-specific reference intervals for thyroid hormones during pregnancy in an iodine-sufficient area of the Mediterranean, Crete, Greece. This project was performed in the context of “Rhea” mother-child cohort. Fulfillment of extensive questionnaires and estimation of free triiodothyronine (fT3), free thyroxine (fT4), thyroid-stimulating hormone (TSH), and antithyroid antibodies were performed. The reference population was defined using inclusion criteria regarding thyroidal, obstetric, and general medical status of women. Reference interval for TSH was 0.05–2.53 μIU/mL for the first and 0.18–2.73 μIU/mL for the second trimester. 6,8% and 5,9% of women in the first and second trimester, respectively, had TSH higher than the upper reference limit. These trimester-specific population-based reference ranges are essential in everyday clinical practice for the correct interpretation of thyroid hormone values and accurate classification of thyroid disorders.

27 April 2021 in Microorganisms
Verified
Journal Article
Open access
PDF file
AVAlexandra Vasilakopoulou
Alexandra Vasilakopoulou
PKPolyxeni Karakosta
Polyxeni Karakosta
SVSophia Vourli
Sophia Vourli
EKEleni Kalogeropoulou
Eleni Kalogeropoulou
Spyros PournarasSpyros Pournaras
Spyros Pournaras
We report a preliminary evaluation of the NG-Test CARBA 5 immunochromatographic assay for detecting carbapenemases directly from rectal swabs on the same day of sampling. Thirty fecal swabs were examined for carbapenemase-producing organisms (CPOs) by conventional culture, PCR, and NG-Test CARBA 5. Each sample was tested by the immunochromatographic assay five times, including direct testing and incubation in trypticase soy broth for 1, 2, 3, and 4 h. Twenty patients yielded CPOs by culture. Immunochromatographic and PCR results were concordant and detected the same 25 carbapenemases (11 KPC, 8 VIM, and 6 NDM). In five cases, we detected co-carriage of KPC and VIM. Compared with PCR, the sensitivity of NG-Test CARBA 5 for the detection of KPC, VIM, and NDM was 80% without incubation, 88% with one hour, 92% with two, and 100% with three hours incubation, while specificity was 100% for all time points. All samples containing adequate fecal content were detected by NG-Test CARBA 5 concordantly with PCR, without incubation. NG-Test CARBA 5 is a reliable test that rapidly detects the presence of carbapenemases at the same day of sampling, directly from rectal swabs. It thus provides early information to guide antimicrobial treatment and infection control interventions.

1 November 2021 in Environmental Pollution
Verified
Journal Article
Closed access
KMKaterina Margetaki
Katerina Margetaki
MVMarina Vafeiadi
Marina Vafeiadi
MKMariza Kampouri
Mariza Kampouri
TRTheano Roumeliotaki
Theano Roumeliotaki
PKPolyxeni Karakosta
Polyxeni Karakosta
LCLeda Chatzi
Leda Chatzi

26 March 2024 in European Journal of Clinical Microbiology & Infectious Diseases
Verified
Journal Article
Open access
PDF file
PKPolyxeni Karakosta
Polyxeni Karakosta
SVSophia Vourli
Sophia Vourli
EKElisavet Kousouli
Elisavet Kousouli
Georgios MeletisGeorgios Meletis
Georgios Meletis
ATAreti Tychala
Areti Tychala
Spyros PournarasSpyros Pournaras
Spyros Pournaras
From 2019 (pre-COVID-19) to 2022 (COVID-19 years), three tertiary Greek hospitals monitored MDRO bloodstream infection (BSI) and hospital acquisition relying on laboratory data. Surveillance covered carbapenem-resistant Enterobacterales (CRE), Acinetobacter baumannii (CRAB), Pseudomonas aeruginosa (CRPA), vancomycin-resistant enterococci (VRE), and methicillin-resistant Staphylococcus aureus (MRSA), in intensive care units (ICUs) and non-ICUs. Non-ICUs experienced significant increases in CRE, CRAB and VRE during the pandemic. In ICUs, CRE increased in 2021, CRAB in 2020 and 2021, and VRE in 2021 and 2022. KPC predominated among CRE. MDRO BSI and hospital acquisition incidence rates increased, driven by CRE and CRAB.